GANX Gain Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1819411 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7.3%
TTM EPS YoY31.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-223.9%
ROA-148.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets23.3%
Debt / equity0.03x
Current ratio5.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $55,180 | $140,108 | $164,994 |
| R&D expense | $10.21M | $10.79M | $11.52M | $8.38M | $7.16M |
| SG&A expense | $8.50M | $9.56M | $10.79M | $9.54M | $6.83M |
| Operating income | -$18.71M | -$20.35M | -$22.25M | -$17.78M | -$13.83M |
| Interest expense | — | — | — | — | $0 |
| Pretax income | -$19.30M | -$19.87M | -$22.19M | -$17.50M | -$13.89M |
| Income tax | $861,118 | $536,815 | $79,275 | $92,976 | $4,008 |
| Net income | -$20.16M | -$20.41M | -$22.27M | -$17.59M | -$13.89M |
| EBITDA | -$18.62M | -$20.27M | -$22.17M | -$17.71M | -$13.81M |
| EPS (basic) | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 |
| EPS (diluted) | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 |
| Weighted avg. shares (diluted) | 32.97M | 22.88M | 13.01M | 11.88M | 10.17M |
| Banking | |||||
| Net interest income | — | — | $494,234 | $375,357 | $12,495 |
| Balance sheet | |||||
| Cash & equivalents | $20.84M | $10.42M | $11.83M | $7.34M | $36.91M |
| Short-term investments | — | — | $5.00M | $12.83M | — |
| Current assets | $22.24M | $11.60M | $17.78M | $21.09M | $37.72M |
| PP&E, net | $74,916 | $103,619 | $125,962 | $144,379 | $105,986 |
| Intangibles | $102,837 | — | — | — | — |
| Total assets | $22.82M | $12.12M | $18.61M | $24.10M | $38.99M |
| Current liabilities | $3.35M | $3.91M | $4.95M | $4.13M | $2.55M |
| Short-term debt | $100,869 | $110,177 | $118,797 | $108,135 | $103,826 |
| Long-term debt | $300,084 | $328,327 | $449,053 | $495,258 | $590,468 |
| Total debt | $400,953 | $438,504 | $567,850 | $603,393 | $694,294 |
| Total liabilities | $4.25M | $4.78M | $6.03M | $5.22M | $4.17M |
| Shareholders' equity | $18.56M | $7.34M | $12.58M | $18.88M | $34.82M |
| Net debt | -$20.44M | -$9.98M | -$11.26M | -$6.74M | -$36.22M |
| Shares outstanding | 42.07M | 27.13M | 16.21M | 11.88M | 11.88M |
| Cash flow statement | |||||
| Operating cash flow | -$18.47M | -$18.87M | -$18.87M | -$14.69M | -$12.37M |
| Capital expenditure | — | $22,493 | $15,358 | $118,953 | $94,212 |
| Free cash flow | — | -$18.90M | -$18.88M | -$14.81M | -$12.46M |
| Investing cash flow | — | $4.98M | $10.22M | -$14.77M | -$94,212 |
| Financing cash flow | $28.45M | $13.01M | $12.64M | -$78,774 | $41.77M |
| Depreciation & amortization | $94,046 | $84,071 | $83,579 | $64,168 | $15,484 |
| Stock-based compensation | $1.80M | $2.39M | $3.26M | $1.53M | $839,371 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.